logo-loader
viewCyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals CEO reveals key milestone data

Cyclacel Pharmaceuticals, Inc (NASDAQ:CYCC) CEO Spiro Rombotis joined Proactive at the Biotech Showcase 2020 in San Francisco. The New Jersey-based company recently announced preliminary data from two of the company’s Phase 1 studies aiming to treat patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes and chronic lymphocytic leukemia.

Quick facts: Cyclacel Pharmaceuticals Inc

Price: 5.36 USD

NASDAQ:CYCC
Market: NASDAQ
Market Cap: $26.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator’s 'solid pandemic plan' to see company much stronger on other side

Xpediator (LON:XPD) chief financial officer Robert Ross joins Steve Darling from Proactive ahead of its AGM. Ross talks about its pandemic management plan, its pipeline of acquisition opportunities and how financially secure the company is.

17 minutes ago

2 min read